Targeting Renal Cell Carcinoma with a HIF-2 antagonist

Clear cell Renal Cell Carcinoma (ccRCC) is characterized by VHL inactivation(1,2). Because no other gene is mutated as frequently, and VHL mutations are truncal(3), VHL inactivation is regarded as the governing event(4). VHL loss activates HIF-2, and constitutive HIF-2 restores tumorigenesis in VHL-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nature
Main Authors: Chen, Wenfang, Hill, Haley, Christie, Alana, Kim, Min Soo, Holloman, Eboni, Pavia-Jimenez, Andrea, Homayoun, Farrah, Ma, Yuanqing, Patel, Nirav, Yell, Paul, Hao, Guiyang, Yousuf, Qurratulain, Joyce, Allison, Pedrosa, Ivan, Geiger, Heather, Zhang, He, Chang, Jenny, Gardner, Kevin H., Bruick, Richard K., Reeves, Catherine, Hwang, Tae Hyun, Courtney, Kevin, Frenkel, Eugene, Sun, Xiankai, Zojwalla, Naseem, Wong, Tai, Rizzi, James P., Wallace, Eli M., Josey, John A., Xie, Yang, Xie, Xian-Jin, Kapur, Payal, McKay, Renée M., Brugarolas, James
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5340502/
https://ncbi.nlm.nih.gov/pubmed/27595394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature19796
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados